1	
2	
3	
4	Machine learning for improved dengue diagnosis, Puerto Rico
5	
6	Zachary J. Madewell, PhD ^{1*} ; Dania M. Rodriguez, MS ¹ ; Maile B. Thayer, PhD ¹ ; Vanessa Rivera-Amill,
7	PhD ² ; Jomil Torres Aponte, MS ^{1,3} ; Melissa Marzan-Rodriguez, DrPH ³ ; Gabriela Paz-Bailey, MD, PhD ¹ ;
8	Laura E. Adams, DVM ¹ ; Joshua M. Wong, MD ¹
9	
10	¹ Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
11	² Ponce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico.
12	³ Division of Epidemiology & Research, Puerto Rico Department of Health, San Juan, Puerto Rico.
13	
14	*Correspondence to: Zachary J. Madewell, Division of Vector-Borne Diseases, Centers for Disease

15 Control and Prevention, San Juan, Puerto Rico; email: <u>ock0@cdc.gov</u>

Background: Diagnosing dengue accurately, especially in resource-limited settings, remains

16 Abstract

17

18 challenging due to overlapping symptoms with other febrile illnesses and limitations of current diagnostic 19 methods. This study aimed to develop machine learning (ML) models that leverage readily available 20 clinical data to improve diagnostic accuracy for dengue, potentially offering a more accessible and rapid 21 diagnostic tool for healthcare providers. 22 **Methods:** We used data from the Sentinel Enhanced Dengue Surveillance System (SEDSS) in Puerto 23 Rico (May 2012—June 2024). SEDSS primarily targets acute febrile illness but also includes cases with 24 other symptoms during outbreaks (e.g., Zika and COVID-19). ML models (logistic regression, random 25 forest, support vector machine, artificial neural network, adaptive boosting, light gradient boosting 26 machine [LightGBM], and extreme gradient boosting [XGBoost]) were evaluated across different feature 27 sets, including demographic, clinical, laboratory, and epidemiological variables. Model performance was 28 assessed using the area under the receiver operating characteristic curve (AUC), where higher AUC 29 values indicate better performance in distinguishing dengue cases from non-dengue cases. 30 **Results:** Among 49,679 patients in SEDSS, 1,640 laboratory-confirmed dengue cases were 31 identified. The XGBoost and LightGBM models achieved the highest diagnostic accuracy, with AUCs exceeding 90%, particularly with comprehensive feature sets. Incorporating predictors such as monthly 32 33 dengue incidence, leukopenia, thrombocytopenia, rash, age, and absence of nasal discharge significantly 34 enhanced model sensitivity and specificity for diagnosing dengue. Adding more relevant clinical and 35 epidemiological features consistently improved the models' ability to correctly identify dengue cases. 36 **Conclusions:** \Box ML models, especially XGBoost and LightGBM, show promise for improving diagnostic 37 accuracy for dengue using widely accessible clinical data, even in resource-limited settings. Future 38 research should focus on developing user-friendly tools, such as mobile apps, web-based platforms, or 39 clinical decision systems integrated into electronic health records, to implement these models in clinical 40 practice and exploring their application for predicting dengue.

41

42 Keywords: dengue; machine learning; diagnosis; Caribbean; extreme gradient boosting

43 Author summary

44 Dengue is a tropical disease caused by the dengue virus, which is transmitted by mosquitoes. It affects 45 millions of people worldwide every year, leading to severe illness and even death in some cases. Accurate 46 and timely diagnosis of dengue is crucial for proper treatment and controlling the spread of the virus. 47 Traditionally, diagnosing dengue relies on symptoms and laboratory tests, which can sometimes be non-48 specific and not immediately available in distinguishing dengue from other similar illnesses. In our study, 49 we explored the use of machine learning, a type of artificial intelligence, to improve dengue diagnosis 50 using patient information from Puerto Rico. Our models, which use information like age, symptoms, and 51 specific blood cell counts, can accurately predict whether someone has dengue. We found that some 52 simple information, like whether a patient has a rash or low blood cell counts, can be very helpful in 53 making a diagnosis. While more complex models performed slightly better, simpler models can also be 54 effective, especially in places with limited resources. Our study shows that using computer models can 55 improve dengue diagnosis and help healthcare providers make better decisions for their patients.

56 Introduction

57	Dengue, a mosquito-borne viral infection transmitted by Aedes mosquitoes, is a significant global
58	public health threat. Endemic in over 100 countries and affecting 2.5 billion people at risk, the virus poses
59	a substantial burden on healthcare systems worldwide [1-3]. Dengue is caused by four distinct dengue
60	viruses, also known as serotypes (DENV-1, -2, -3, and -4) that can lead to a spectrum of clinical
61	presentations. These range from asymptomatic infections to debilitating illness, and in severe cases,
62	potentially life-threatening complications like dengue hemorrhagic fever and dengue shock syndrome [4-
63	6]. Globally, dengue is estimated to cause 390 million infections [7] and 40,500 deaths annually [8].
64	The United States unincorporated territory of Puerto Rico has a long history with dengue, with
65	the first reported outbreak in 1899 [9]. Puerto Rico accounts for over 95% of all locally acquired dengue
66	cases reported within the United States [10, 11]. Transmission follows a seasonal pattern, with large
67	outbreaks typically occurring every three to five years [12]. From 2010–2020, dengue was associated with
68	nearly 30,000 confirmed and probable cases including 584 severe cases, 10,000 hospitalizations, and 68
69	deaths island-wide [11]. A large epidemic in Puerto Rico occurred in 2012–2013, dominated by DENV-1,
70	although sporadic cases of DENV-4 also occurred. During 2016–2023, cases remained relatively low
71	compared to historical levels. However, in early 2024, a concerning surge in cases prompted a public
72	health emergency declaration by Puerto Rico's Department of Health. The outbreak has placed increased
73	pressure on the healthcare system, which was already strained by the ongoing syndemic of dengue,
74	influenza, and COVID-19 [13]. Particularly, high bed occupancy observed in June 2024 due to COVID-
75	19 has underscored the urgent need for improved diagnostic methods and effective public health
76	interventions to manage and control the spread of dengue and other co-circulating pathogens.
77	Diagnosing dengue accurately can be difficult, particularly in the early stages of the illness, due
78	to overlapping symptoms with other febrile illnesses and the need for repeated evaluations to distinguish
79	dengue from other conditions as the illness progresses. Current diagnostic methods have their limitations

80 as well. Laboratory tests for dengue, such as RT-PCR or serologic assays, require specialized equipment

81 and expertise, are often unavailable in resource-limited settings, and can take several days to return results, making them less suitable for guiding immediate clinical management decisions. These tests also 82 83 have limited windows of detection; for example, PCR is most sensitive in the first week of illness, while 84 serologic tests are more useful later, potentially missing cases depending on when patients present for 85 care. Rapid tests, while faster, have limitations in sensitivity, can be costly, and have not been authorized 86 for use in the United States. As a result, many dengue cases are not confirmed in time to guide clinical 87 decisions, which can impact patient care, public health efforts, and accurate reporting of disease burden. 88 For example, during outbreaks, many cases are clinically diagnosed based on symptoms and 89 epidemiological context, as laboratory resources are often prioritized for severe cases or sentinel 90 surveillance rather than confirming every suspected case. 91 This project proposes a novel approach to address these challenges by developing machine 92 learning (ML) models for diagnosing dengue fever. These models leverage readily available data from the 93 Sentinel Enhanced Dengue Surveillance System (SEDSS) in Puerto Rico, including demographics, 94 symptoms, laboratory, and other factors. The models could be integrated into existing electronic health 95 records (EHR) systems to assist clinicians in making timely diagnoses [14]. In clinical practice, the ML 96 model could automatically analyze patient data upon entry, generating a risk score for dengue based on 97 the combination of symptoms, patient history, and other available data [15]. When the model identifies a 98 high probability of dengue, it would alert the clinician through the EHR system, prompting further 99 investigation or specific diagnostic testing. This approach has been successfully used in other diseases, 100 such as COVID-19 [16], infective endocarditis [17], and incident atrial fibrillation [18], where ML 101 models are embedded into EHRs to provide early warnings for timely interventions, improving patient 102 outcomes. 103 In resource-limited settings where EHR systems may not be universally available, these models 104 could be adapted for use on portable devices like smartphones or tablets, enabling healthcare workers to

105 input patient data and receive a risk score even when access to advanced diagnostic tools is limited. This

106 flexibility ensures that the benefits of ML-driven diagnostic support can be extended beyond well-

107 resourced environments.

108	By tapping into the growing adoption of EHRs worldwide, ML models can offer a solution that is
109	not constrained by the physical limitations of laboratory resources. In many regions, even where basic
110	laboratory facilities are lacking, EHR systems are being rapidly adopted, allowing healthcare providers to
111	store and analyze patient data electronically. This technological advancement presents a unique
112	opportunity for ML to enhance diagnostic accuracy and provide timely insights using data that is already
113	being collected. To identify the optimal approach, we compare the performance of multiple ML
114	algorithms and sampling techniques alongside traditional logistic regression analysis. By using ML, this
115	project aims to improve diagnostic accuracy for dengue compared to traditional methods, provide a rapid
116	and accessible tool for resource-limited settings, and potentially reduce misdiagnosis rates to improve
117	patient outcomes. This project aligns with the growing body of research exploring the use of ML for
118	infectious disease diagnosis, particularly in areas with limited diagnostic resources [19-22].

119

120 Methods

121 Study population

122 In this analysis, we used data from SEDSS, an ongoing facility-based study in Puerto Rico that 123 tracks the frequency and causes of acute febrile illness [23, 24]. Since its inception in 2012, SEDSS has 124 included five sites: 1) Saint Luke's Episcopal Hospital (SLEH) in Ponce, a tertiary acute care facility (2012-present), 2) SLEH-Guayama, a secondary acute care hospital (2013-2015), 3) Hospital de La 125 126 Universidad de Puerto Rico in Carolina, another secondary acute care teaching hospital (2013–2015), 4) 127 Centro de Emergencia y Medicina Integrada (CEMI), an outpatient acute care clinic in Ponce (2016-128 present), and 5) Auxilio Mutuo Hospital, a tertiary care facility in the San Juan Metro Area (2018– 129 present). The data used for this analysis was downloaded from SEDSS on July 25, 2024.

130

131 Study enrollment and data collection

132	Participants in SEDSS are enrolled through convenience sampling. Potential participants are
133	identified by triage nurses as any patient with an acute febrile illness (AFI) defined by the presence of
134	fever (\geq 38.0°C for temperatures measured orally, \geq 37.5°C for temperatures measured rectally, and
135	\geq 38.5°C for temperatures measured axillary) at the time of triage or chief complaint of having a fever
136	within the past 7 days. During the Zika epidemic in Puerto Rico (June 2016–June 2018), patients were
137	eligible if they presented with either rash and conjunctivitis, rash and arthralgia, or fever [25]. Starting in
138	April 2020, patients with cough or dyspnea within the last 14 days (with or without fever) were also
139	eligible to better capture respiratory viruses [13]. No age groups were excluded, although infants were
140	only eligible for enrollment if they presented to the hospital after their initial discharge after birth. After
141	meeting the inclusion criteria and being informed about the study, participants provided written informed
142	consent. In cases where patients were incapacitated at the time of triage due to acute illness, consent was
143	sought after their stabilization.
144	Data collection in SEDSS involves patient interviews and medical record reviews at both
145	enrollment and convalescence (~7-14 days later). The case investigation form (CIF) gathers
146	demographics, comorbidities, and clinical features. The convalescent sample processing form (CSPF)
147	echoes CIF data, adding the second specimen collection date and AFI severity indicators
148	(hospitalizations, clinic visits). Initially paper-based (CIF/CSPF), data collection transitioned to electronic
149	format in 2020 using REDCap on Android tablets [26, 27].
150	

151 Sample collection and laboratory procedures

Blood, nasopharyngeal (NP), and oropharyngeal (OP) specimens were collected at enrollment from eligible participants. Additional blood samples (serum and whole blood) were also collected during the convalescent phase. Participation required providing at least one sample (blood or OP/NP swab). All patients had molecular testing for dengue virus for specimens collected within 7 days of symptom onset.

156	Serologic testing for anti-DENV antibodies was performed using Immunoglobulin M (IgM) antibody
157	capture enzyme-linked immunosorbent assay (ELISA) for specimens collected >3 days after symptom
158	onset (6). Dengue cases were defined as a positive result for DENV by RT-PCR or DENV IgM.
159	

160 Variable selection

161 Our variable selection process was designed to identify features at the initial clinical presentation 162 that could assist in accurately diagnosing laboratory-confirmed dengue cases. We began by considering 163 54 variables based on physicians' medical knowledge and clinical experience. These variables included 164 demographic characteristics, recent travel history, warning signs, other clinical signs, and laboratory 165 findings. Additionally, dengue monthly incidence in Puerto Rico during 2012 to 2024 was obtained from 166 the Puerto Rico Passive Arboviral Disease Surveillance System (PADSS). This data informed prior 167 knowledge that could influence a physician's dengue diagnosis, consistent with previous research [21]. 168 To refine feature selection, we used logistic regression to calculate crude unadjusted odds ratios 169 for each of the 54 variables. The use of unadjusted odds ratios allowed us to quickly assess the strength of 170 association between each variable and dengue diagnosis without the complexity of adjusting for 171 confounders at this stage. This step helped to screen variables and group them into feature sets based on 172 their association with dengue, as indicated by the magnitude of their odds ratios. The rationale for this 173 approach is that, in clinical practice, certain variables with strong associations (e.g., high or low odds 174 ratios) may be more immediately relevant for consideration in a diagnostic model. This is particularly 175 useful in scenarios where we want to simplify the feature selection process while still capturing the most 176 impactful predictors. By using different odds ratio cutoffs (e.g., >6 or <0.17, >3 or <0.33, >2 or <0.50), 177 we created four groups of variables with varying levels of association strength. Additionally, we included 178 a group of variables that were statistically significant at p < 0.05, to ensure that we did not overlook 179 potentially important features with more moderate associations.

180 The decision to use these crude odds ratios to define feature sets was driven by the need for a 181 straightforward and clinically intuitive method to narrow down the initial list of 54 variables before applying more complex ML models. Although ML algorithms can automatically select and weight 182 183 features during model training, this initial step allowed us to focus on variables that were already known 184 to be clinically relevant or strongly associated with dengue, simplifying the interpretation of the models 185 for clinicians. The final feature sets were then evaluated using various ML models to determine their 186 predictive performance. The rationale for evaluating different sized feature sets was to understand how 187 model performance might change as we included more or fewer variables. This approach helped us 188 balance the trade-off between model complexity and predictive accuracy, particularly when considering 189 the potential application of these models in different clinical settings. 190 Although previous dengue infection is a known risk factor for developing severe disease and can 191 influence clinical presentation, it was excluded from the primary analysis due to limitations in its 192 applicability to routine clinical practice. Immunoglobulin G (IgG) testing is not universally available, and 193 interpreting positive IgG results can be challenging for clinicians, potentially leading to misdiagnosis. 194 However, to assess the potential impact of this variable on model performance, we conducted an 195 additional analysis incorporating a history of prior dengue infection (confirmed by IgG) as an additional feature in the highest performing model within each feature set. To further explore the performance of the 196 197 models in resource-constrained settings, where complete blood counts (CBCs) might not be readily 198 available, we conducted an additional subanalysis excluding leukopenia and thrombocytopenia from the 199 highest performing models within each feature set.

200

201 Sampling

To address class imbalance in our dataset, we used downsampling to ensure an equal representation of dengue-positive and dengue-negative cases [28]. Class imbalance, where denguepositive cases are significantly outnumbered by dengue-negative cases, can bias ML models towards the

majority class, reducing their ability to accurately predict minority class outcomes. Downsampling mitigates this issue by randomly reducing the number of majority class instances to match the number of minority class instances, thus balancing the dataset and improving the model's ability to accurately classify dengue-positive cases. This process was performed using the downSample function from the caret package in R [29], setting the ratio of positive to negative cases to 1:1. The datasets were then randomly partitioned into training and testing sets using a 70:30 ratio. The training sets were used to train the ML models, whereas the testing set was reserved for model evaluation.

212

213 Machine learning models

214 We used an initial logistic regression model as a baseline to explore the relationship between 215 potential predictors and dengue diagnosis outcomes. This model was trained using the same groups of 216 variables based on different odds ratio cutoffs as mentioned earlier: variables with odds ratios >6, >3, >2, 217 and any variables significant at p<0.05. Stepwise selection was used to iteratively add or remove variables 218 to identify the optimal model with the lowest Akaike Information Criterion (AIC). This approach 219 balances model complexity and goodness-of-fit by selecting variables that contribute significantly to the 220 model. The final logistic regression model, derived from stepwise selection, was evaluated on both the 221 training and testing sets.

222 Six ML methods were used to predict dengue infections and assess feature importance. These 223 algorithms were selected to represent a breadth of ML predictive models and reflect those commonly used 224 as diagnostic tools for various diseases. The algorithms used include Random Forest (RF), Support 225 Vector Machine (SVM), Artificial Neural Network (ANN), Adaptive Boosting (AdaBoost), Light 226 Gradient Boosting Machine (LightGBM), and eXtreme Gradient Boosting (XGBoost). RF is an ensemble 227 learning method that constructs multiple decision trees during training and outputs the mode of their 228 predictions for classification or the mean prediction for regression [30]. SVM is a supervised learning 229 algorithm that finds the optimal hyperplane to separate data points of different classes in the feature space

230 [31]. ANN is a computational model inspired by the way biological neural networks work, consisting of 231 interconnected nodes (neurons) that process input data to learn and make predictions [32]. AdaBoosting is 232 an ensemble technique that combines the predictions of several weak classifiers to create a strong 233 classifier by focusing more on the instances that previous classifiers misclassified [33]. LightGBM is a 234 fast, distributed, high-performance gradient boosting framework that uses tree-based learning algorithms 235 for efficient and accurate predictions [34]. XGBoost is an optimized gradient boosting framework that 236 uses decision trees and a range of enhancements for improved performance and speed in predictive 237 modeling [34]. In this study, we specifically used the "gbtree" booster, which implements decision tree-238 based gradient boosting for learning the model. 239 For parameter optimization, we used a grid search to evaluate different combinations of 240 hyperparameter values, and the area under the receiver operating characteristic curve (AUC-ROC) was 241 used as the optimization metric. We used 5-fold cross-validation during model training to ensure 242 robustness and reduce overfitting. Specific details of the grid search strategy and parameters included in 243 each model are provided in the Table S2. For gradient boosting models, the training process used 100 244 boosting rounds with early stopping if the evaluation metric did not improve for 10 rounds. The R 245 packages randomForest [35], e1071 [36], nnet [37], ada [38], lightgbm [39], and xgboost [40], were used for implementing RF, SVM, ANN, AdaBoost, LightGBM, and XGBoost models, respectively. 246 247

248 **Performance evaluation**

Model performance was evaluated on both the training and testing sets using AUC-ROC as the primary performance metric. AUC-ROC is an aggregate measure of performance across all possible classification thresholds, providing a comprehensive assessment of the model's ability to distinguish between classes. We used the DeLong method to calculate the confidence intervals for the AUC-ROC to ensure accurate estimation of the model's performance [41]. Additionally, confusion matrices were generated to assess the model's classification performance in terms of sensitivity, specificity, and

accuracy. The optimal threshold for classification was determined using Youden's index from the ROC
 curve [42]. Cohen's kappa was also calculated to measure the agreement between predicted and observed
 classifications, accounting for chance agreement.

258 Feature importance was assessed for each ML model. By quantifying each feature's contribution 259 to the model's accuracy, we can identify the most influential features to better understand and improv 260 predictions for each method. For RF, AdaBoost, LightGBM, and XGBoost, we used the varImp, varplot, 261 lgb.importance, and xgb.importance functions from the randomForest [35], ada [38], lightgbm [39], and 262 xgboost [40] packages. For SVM, we determined feature importance by calculating the absolute value of 263 the coefficients from the support vectors. For ANN, we used permutation importance [43], which works by calculating the original AUC-ROC as a baseline, then permuting each feature to break its relationship 264 265 with the target variable and recalculating the AUC-ROC. The importance of a feature is determined by 266 the decrease in AUC-ROC after permutation; a significant drop indicates high importance. Predicted 267 probabilities were uniformly binned, with mean predicted probabilities and observed positive case 268 proportions calculated for each bin. All analyses were done using R version 4.4.0 [44].

269

Post-hoc subanalysis: Evaluating AUC with sequential feature

271 addition

After identifying feature sets based on crude odds ratios in the primary analysis, we performed a post-hoc subanalysis to evaluate model performance by sequentially adding the most important features from the highest-performing ML model. This approach simulates a refined diagnostic process where key features are known in advance. By recalculating AUC with each feature added, we assessed the incremental benefit of each and identified the minimum set of variables for optimal performance. This analysis also tested the robustness of our primary feature selection by comparing it to ML-derived feature importance.

280

Ethics statement

282	The Institutional Review Boards at the Centers for Disease Control and Prevention (CDC),
283	Auxilio Mutuo, and Ponce Medical School Foundation approved the SEDSS study protocols 6214, and
284	120308-VR/2311173707, respectively. Written consent to participate was obtained from all adult
285	participants and emancipated minors. For minors aged 14 to 20 years, written consent was obtained, and
286	for those aged 7 to 13 years, parental written consent and participant assent were obtained.
282	

287

288 **Results**

289 **Participant Characteristics**

290 From May 2012 to June 2024, 51,219 unique AFI visits were recorded from 41,180 participants 291 enrolled in SEDSS, including 8,035 hospitalizations or transfers and 73 deaths. Of these visits, there were 292 49,679 AFI visits from 40,124 participants tested for DENV. The median age among was 15 years 293 (interquartile range (IQR): 4, 38) and 52.8% were female (Table 1). From these, 1,640 (3.3%) had dengue 294 (1,167 positive by RT-PCR, 473 positive by DENV IgM), 1,026 (62.5%) of which occurred during the 295 2012–2013 epidemic. SEDSS participants tested positive for other arboviruses including chikungunya 296 (n=2,291) and Zika (n=1,899), and respiratory viruses including influenza A (n=4,296), influenza B 297 (n=1,726), human adenovirus (n=1,835), respiratory syncytial virus (n=1,576), and SARS-CoV-2 298 (n=2,322), among others (S3 Table). The majority of the 1,155 serotyped dengue cases were DENV-1 299 (n=903, 78.2%), followed by DENV-3 (n=111, 9.6%), DENV-2 (n=91, 7.9%), and DENV-4 (n=50, 300 4.3%). Of 1,640 dengue cases, 737 (44.9%) were hospitalized or transferred, and two (0.1%) died. 301 Median duration from symptom onset to presentation at the emergency room was 3 days [IQR: 1, 4] for 302 dengue cases. A previous dengue infection, as indicated by a positive IgG test on or before the fifth day of 303 illness, was present in 79.1% (n=564/713) of dengue cases tested. Additionally, 38.5% (n=632) had at

least one comorbidity, including obesity (28.4%), chronic pulmonary disease (20.2%), and hypertension

305 (9.0%).

306

 Table 1. Demographic and clinical characteristics of participants (dengue and non-dengue cases), SEDSS, May 2012–June 2024. Dengue cases had a positive result for dengue by RT-PCR or IgM.

Total cases N=49679 N=1640 N=46039 N=46039 Month			Laboratory-		
$\begin{tabular}{ c c c c c c } \hline Total & dengue cases & cases \\ N = 48679 & N = 1460 & N = 48039 \\ \hline & & & & & & & & & & & & & & & & & &$			confirmed	Non-dengue	
N = 49679N = 1640N = 48039Image: N = 1640n (%)n (%)n (%)p valueMonth3706 (7.5)133 (8.1)3573 (7.4)January3792 (7.6)102 (6.2)3690 (7.7)March3995 (7.9)71 (4.3)3334 (8.0)April3939 (7.9)78 (4.8)3861 (8.0)May4291 (8.6)107 (6.5)4184 (8.7)June4377 (8.6)157 (9.6)4220 (8.8)July4317 (8.7)144 (8.8)4173 (8.7)August4489 (9.0)171 (10.4)4318 (9.0)September4436 (8.8)163 (9.9)4203 (8.7)October4423 (8.9)162 (9.9)4221 (8.9)November3800 (7.8)153 (9.3)3737 (7.8)December3902 (16.6)694 (6.5)29622 (65.2)4-66587 (14.0)621 (41.3)5966 (13.1)7+1633 (3.5)65 (4.3)158 (3.5)Age group<0.0013294 (14.4)6406 (13.3)10-19734 (14.9)65 (4.5)20-295865 (11.8)211 (12.9)50+8432 (17.0)156 (13.1)1-410539 (21.2)107 (6.5)50+8432 (17.0)156 (13.3)10-19734 (14.9)656 (4.5)20-295865 (11.8)20-295865 (11.8)20-295865 (11.8)20-295865 (11.8)20-403294 (6.6)30-394046 (8.1)40-493294 (6.6) </th <th></th> <th>Total</th> <th>dengue cases</th> <th>cases</th> <th></th>		Total	dengue cases	cases	
n (%) n (%) n (%) p-value Month <0.001 January 3706 (7 5) 133 (8 1) 3573 (7 4) February 3792 (7 6) 102 (6 2) 3680 (7 7) March 3905 (7 9) 71 (4 3) 3834 (8 0) April 3939 (7 9) 78 (4 8) 3834 (8 0) May 4291 (8 6) 107 (6 5) 4184 (8 7) June 4377 (8 8) 157 (9 6) 4220 (8 8) July 4317 (8 7) 144 (8 8) 4173 (8 7) August 4489 (9 0) 171 (10.4) 4318 (9 0) September 4366 (8 8) 163 (9 9) 4261 (8 9) November 4184 (8 1) 199 (12 1) 3985 (8 3) December 3890 (7 8) 119 (7 9) 8244 (18 2) 1-3 30321 (64 6) 699 (46.5) 29622 (65 2) 4-6 6587 (14 0) 621 (41.3) 5966 (13.1) 7+ 1053 (3 5) 65 (4.3) 1568 (3.5) Age group 640 (13.4)		N = 49679	N = 1640	N = 48039	
Month		n (%)	n (%)	n (%)	p-value
January 3706 (7 5) 133 (8 1) 3573 (7 4) February 3792 (7 6) 102 (6 2) 3690 (7 7) March 3939 (7 9) 78 (4.8) 3864 (8 0) April 3939 (7 9) 78 (4.8) 3864 (8 0) May 4291 (8 6) 107 (6 5) 4184 (8 7) June 4377 (8 8) 157 (9 6) 4220 (8 8) July 4317 (8 7) 144 (8 8) 4173 (8 7) August 4489 (9 0) 171 (10 4) 4318 (9 0) September 4366 (8 8) 163 (9 9) 4203 (8 7) October 4423 (8 9) 162 (9 9) 4203 (8 7) October 4423 (8 9) 153 (9 3) 373 (7 8) December 3990 (7 8) 153 (9 3) 373 (7 8) O 8363 (17 8) 119 (7 9) 8244 (18 2) 1-3 30321 (64 6) 699 (46 5) 29622 (65 2) 4-6 6587 (14 0) 621 (41.3) 5966 (13 1) 7+ 1633 (3 5) 65 (4 3) 1568 (3 5) Age group <0.001	Month				<0.001
February 3792 (7.6) 102 (6.2) 3690 (7.7) March 3905 (7.9) 71 (4.3) 3834 (8.0) April 3939 (7.9) 78 (4.8) 3861 (8.0) May 4291 (8.6) 107 (6.5) 4184 (8.7) June 4377 (8.8) 157 (9.6) 4220 (8.8) July 4317 (8.7) 144 (8.8) 4173 (8.7) August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 162 (9.9) 4261 (8.9) November 23890 (7.8) 153 (9.3) 3737 (7.8) December 3890 (7.8) 153 (9.3) 3737 (7.8) Days post onset	January	3706 (7.5)	133 (8.1)	3573 (7.4)	
March 3905 (7 9) 71 (4.3) 3834 (8.0) April 3939 (7.9) 78 (4.8) 3861 (8.0) May 4291 (8.6) 107 (6.5) 4148 (8.7) June 4377 (8.8) 157 (9.6) 4220 (8.8) July 4317 (8.7) 144 (8.8) 4173 (8.7) August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 162 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (6.3) December 3890 (7.8) 153 (9.3) 3737 (7.8) Days post onset	February	3792 (7.6)	102 (6.2)	3690 (7.7)	
April 3939 (7.9) 78 (48) 3861 (8.0) May 4291 (8.6) 107 (6.5) 4184 (8.7) June 4377 (8.8) 157 (9.6) 4220 (8.8) July 4317 (8.7) 144 (8.8) 4173 (8.7) August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4201 (8.9) November 4423 (8.9) 162 (9.9) 4261 (8.9) December 3890 (7.8) 153 (9.3) 3737 (7.8) Days post onset	March	3905 (7.9)	71 (4.3)	3834 (8.0)	
May 4291 (8.6) 107 (6.5) 4184 (8.7) June 4377 (8.8) 157 (9.6) 4220 (8.8) July 4317 (8.7) 144 (8.8) 4173 (8.7) August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 162 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3890 (7.8) 115 (9.3) 3737 (7.8) Days post onset <	April	3939 (7.9)	78 (4.8)	3861 (8.0)	
June 4377 (8.8) 157 (9.6) 4220 (8.8) July 4317 (8.7) 144 (8.6) 4173 (8.7) August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 162 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3890 (7.8) 119 (7.9) 8244 (18.2) 1.3 30321 (64.6) 6699 (46.5) 29862 (65.2) 4-6 6587 (14.0) 621 (41.3) 5966 (13.1) 7+ 1633 (3.5) 66 (4.3) 1586 (3.5) Age group <0.001	Мау	4291 (8.6)	107 (6.5)	4184 (8.7)	
July 4317 (8.7) 144 (8.8) 4173 (8.7) August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 162 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3890 (7.8) 153 (9.3) 3737 (7.8) O 8363 (17.8) 119 (7.9) 8244 (18.2) 1-3 30321 (64.6) 699 (46.5) 29622 (65.2) 4-6 6587 (14.0) 621 (41.3) 5966 (13.1) 7+ 1633 (3.5) 65 (4.3) 1568 (3.5) Age group	June	4377 (8.8)	157 (9.6)	4220 (8.8)	
August 4489 (9.0) 171 (10.4) 4318 (9.0) September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 162 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3980 (7.8) 119 (7.9) 8244 (18.2) 1.3 30321 (64.6) 699 (46.5) 29622 (65.2) 4-6 6587 (14.0) 621 (41.3) 5966 (13.1) 7+ 1633 (3.5) 65 (4.3) 1568 (3.5) Age group <0.001	July	4317 (8.7)	144 (8.8)	4173 (8.7)	
September 4366 (8.8) 163 (9.9) 4203 (8.7) October 4423 (8.9) 152 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3890 (7.8) 153 (9.3) 3737 (7.8) Days post onset - <0.001	August	4489 (9.0)	171 (10.4)	4318 (9.0)	
October 4423 (8.9) 162 (9.9) 4261 (8.9) November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3890 (7.8) 133 (9.3) 3737 (7.8) Days post onset - 0 8363 (17.8) 119 (7.9) 8244 (18.2) 1-3 30321 (64.6) 699 (46.5) 29622 (65.2) 4-6 6587 (14.0) 621 (41.3) 5966 (13.1) 7+ 1633 (3.5) 65 (4.3) 1568 (3.5) Age group - - 0.001 <1	September	4366 (8.8)	163 (9.9)	4203 (8.7)	
November 4184 (8.4) 199 (12.1) 3985 (8.3) December 3890 (7.8) 153 (9.3) 3737 (7.8) Days post onset < < < < < < < < < < <	October	4423 (8.9)	162 (9.9)	4261 (8.9)	
December 3890 (7.8) 153 (9.3) 3737 (7.8) < Days post onset <	November	4184 (8.4)	199 (12.1)	3985 (8.3)	
Days post onset < <0.001 0 8363 (17.8) 119 (7.9) 8244 (18.2) 1-3 30321 (64.6) 699 (46.5) 29622 (65.2) 4-6 6587 (14.0) 621 (41.3) 5966 (13.1) 7+ 1633 (3.5) 65 (4.3) 1568 (3.5) Age group <1	December	3890 (7.8)	153 (9.3)	3737 (7.8)	
0 8363 (17.8) 119 (7.9) 8244 (18.2) 1-3 30321 (64.6) 699 (46.5) 29622 (65.2) 4-6 6587 (14.0) 621 (41.3) 5966 (13.1) 7+ 1633 (3.5) 65 (4.3) 1568 (3.5) Age group	Days post onset				<0.001
1-3 $30321 (64.6)$ $699 (46.5)$ $29622 (65.2)$ 4-6 $6587 (14.0)$ $621 (41.3)$ $5966 (13.1)$ 7+ $1633 (3.5)$ $65 (4.3)$ $1568 (3.5)$ Age group<1	0	8363 (17.8)	119 (7.9)	8244 (18.2)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1-3	30321 (64.6)	699 (46.5)	29622 (65.2)	
7+1633 (3.5) $65 (4.3)$ $1568 (3.5)$ <0.001 <1 $3449 (6.9)$ $31 (1.9)$ $3418 (7.1)$ $1-4$ $10539 (21.2)$ $107 (6.5)$ $10432 (21.7)$ $5-9$ $6640 (13.4)$ $234 (14.3)$ $6406 (13.3)$ $10-19$ $7394 (14.9)$ $665 (40.5)$ $6729 (14.0)$ $20-29$ $5885 (11.8)$ $211 (12.9)$ $5674 (11.8)$ $30-39$ $4046 (8.1)$ $109 (6.6)$ $3937 (8.2)$ $40-49$ $3294 (6.6)$ $88 (5.4)$ $3206 (6.7)$ $50+$ $8432 (17.0)$ $195 (11.9)$ $8237 (17.1)$ Female sex $26238 (52.8)$ $761 (46.4)$ $25477 (53.0)$ 4046 $197 (0.4)$ $4 (0.2)$ $193 (0.4)$ Bayamon $1041 (2.1)$ $26 (1.6)$ $1015 (2.1)$ Caguas $588 (1.2)$ $28 (1.7)$ $560 (1.2)$ Fajardo $359 (0.7)$ $16 (1.0)$ $343 (0.7)$ Mayaguez $118 (0.2)$ $6 (0.4)$ $112 (0.2)$ Metro $6523 (13.1)$ $352 (21.5)$ $6171 (12.8)$ Ponce $40667 (81.9)$ $1205 (73.5)$ $39462 (82.1)$	4-6	6587 (14.0)	621 (41.3)	5966 (13.1)	
Age group < < < < < < < < < <	7+	1633 (3.5)	65 (4.3)	1568 (3 5)	
<1 $3449 (6.9)$ $31 (1.9)$ $3418 (7.1)$ 1-4 $10539 (21.2)$ $107 (6.5)$ $10432 (21.7)$ 5-9 $6640 (13.4)$ $234 (14.3)$ $6406 (13.3)$ $10-19$ $7394 (14.9)$ $665 (40.5)$ $6729 (14.0)$ $20-29$ $5885 (11.8)$ $211 (12.9)$ $5674 (11.8)$ $30-39$ $4046 (8.1)$ $109 (6.6)$ $3937 (8.2)$ $40-49$ $3294 (6.6)$ $88 (5.4)$ $3206 (6.7)$ $50+$ $8432 (17.0)$ $195 (11.9)$ $8237 (17.1)$ Female sex $26238 (52.8)$ $761 (46.4)$ $25477 (53.0)$ $4046 (8.1)$ $109 (6.6)$ $193 (0.4)$ $40.02)$ $49 (11)$ $4 (0.1)$ $2 (0.1)$ $42 (0.1)$ $40 adilla$ $44 (0.1)$ $2 (0.1)$ $43 (0.7)$ $40 adilla$ $44 (0.1)$ $2 (0.1)$ $42 (0.1)$ $40 adilla$ $44 (0.2)$ $193 (0.4)$ $40 adilla$ $40 (0.1)$ $2 (0.1)$ $40 adilla$ $44 (0.2)$ $103 (0.7)$ $40 adilla$ $44 (0.2)$ $6 (1.6)$ $40 adilla$ $44 (0.2)$ $101 (0.2)$ $40 adilla$ $40 (0.2)$ <td>Age group</td> <td></td> <td></td> <td></td> <td><0.001</td>	Age group				<0.001
1.4 $10539(21.2)$ $107(6.5)$ $10432(21.7)$ 5.9 $6640(13.4)$ $234(14.3)$ $6406(13.3)$ 10.19 $7394(14.9)$ $665(40.5)$ $6729(14.0)$ 20.29 $5885(11.8)$ $211(12.9)$ $5674(11.8)$ 30.39 $4046(8.1)$ $109(6.6)$ $3937(8.2)$ 40.49 $3294(6.6)$ $88(5.4)$ $3206(6.7)$ $50+$ $8432(17.0)$ $195(11.9)$ $8237(17.1)$ Female sex $26238(52.8)$ $761(46.4)$ $25477(53.0)$ $4046(1)$ $2(0.1)$ $42(0.1)$ $42(0.1)$ Aguadilla $44(0.1)$ $2(0.1)$ $42(0.1)$ Aguadilla $44(0.1)$ $2(0.1)$ $42(0.1)$ Arecibo $197(0.4)$ $4(0.2)$ $193(0.4)$ Bayamon $1041(2.1)$ $26(1.6)$ $1015(2.1)$ Caguas $588(1.2)$ $28(1.7)$ $560(1.2)$ Fajardo $359(0.7)$ $16(1.0)$ $343(0.7)$ Mayaguez $118(0.2)$ $6(0.4)$ $112(0.2)$ Metro $6523(13.1)$ $352(21.5)$ $6171(12.8)$ Ponce $40667(81.9)$ $1205(73.5)$ $39462(82.1)$ Uhknown $142(0.3)$ 1001 $141(0.3)$	<1	3449 (6.9)	31 (1.9)	3418 (7.1)	
5-9 $6640(13.4)$ $234(14.3)$ $6406(13.3)$ 10.19 $7394(14.9)$ $665(40.5)$ $6729(14.0)$ 20.29 $5885(11.8)$ $211(12.9)$ $5674(11.8)$ 30.39 $4046(8.1)$ $109(6.6)$ $3937(8.2)$ 40.49 $3294(6.6)$ $88(5.4)$ $3206(6.7)$ $50+$ $8432(17.0)$ $195(11.9)$ $8237(17.1)$ Female sex $26238(52.8)$ $761(46.4)$ $25477(53.0)$ <0.001 Aguadilla $44(0.1)$ $2(0.1)$ $42(0.1)$ Arecibo $197(0.4)$ $4(0.2)$ $193(0.4)$ Bayamon $1041(2.1)$ $26(1.6)$ $1015(2.1)$ Caguas $588(1.2)$ $28(1.7)$ $560(1.2)$ Fajardo $359(0.7)$ $16(1.0)$ $343(0.7)$ Mayaguez $118(0.2)$ $6(0.4)$ $112(0.2)$ Metro $6523(13.1)$ $352(21.5)$ $6171(12.8)$ Ponce $40667(81.9)$ $1205(73.5)$ $39462(82.1)$ Unknown $142(0.3)$ $14(0.1)$ $141(0.3)$	1-4	10539 (21.2)	107 (6.5)	10432 (21.7)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	5-9	6640 (13.4)	234 (14.3)	6406 (13.3)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	10-19	7394 (14.9)	665 (40.5)	6729 (14.0)	
30-39 4046 (8.1) 109 (6.6) 3937 (8.2) 40-49 3294 (6.6) 88 (5.4) 3206 (6.7) 50+ 8432 (17.0) 195 (11.9) 8237 (17.1) Female sex 26238 (52.8) 761 (46.4) 25477 (53.0) <0.001	20-29	5885 (11.8)	211 (12.9)	5674 (11.8)	
40-49 3294 (6.6) 88 (5.4) 3206 (6.7) 50+ 8432 (17.0) 195 (11.9) 8237 (17.1) Female sex 26238 (52.8) 761 (46.4) 25477 (53.0) <0.001	30-39	4046 (8.1)	109 (6.6)	3937 (8.2)	
50+ 8432 (17.0) 195 (11.9) 8237 (17.1) Female sex 26238 (52.8) 761 (46.4) 25477 (53.0) <0.001 Aguadilla 44 (0.1) 2 (0.1) 42 (0.1) <0.001 Aguadilla 44 (0.1) 2 (0.1) 42 (0.1) <0.001 Arecibo 197 (0.4) 4 (0.2) 193 (0.4) Bayamon 1041 (2.1) 26 (1.6) 1015 (2.1) Caguas 588 (1.2) 28 (1.7) 560 (1.2) Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Unknown 142 (0.3) 1 (0.1) 141 (0.3)	40-49	3294 (6.6)	88 (5.4)	3206 (6.7)	
Female sex 26238 (52.8) 761 (46.4) 25477 (53.0) <0.001 Aguadilla 44 (0.1) 2 (0.1) 42 (0.1) <0.001	50+	8432 (17.0)	195 (11.9)	8237 (17.1)	
Health region <0.001 Aguadilla 44 (0.1) 2 (0.1) 42 (0.1) Arecibo 197 (0.4) 4 (0.2) 193 (0.4) Bayamon 1041 (2.1) 26 (1.6) 1015 (2.1) Caguas 588 (1.2) 28 (1.7) 560 (1.2) Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1)	Female sex	26238 (52.8)	761 (46.4)	25477 (53.0)	<0.001
Aguadilla 44 (0.1) 2 (0.1) 42 (0.1) Arecibo 197 (0.4) 4 (0.2) 193 (0.4) Bayamon 1041 (2.1) 26 (1.6) 1015 (2.1) Caguas 588 (1.2) 28 (1.7) 560 (1.2) Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Linknown 142 (0.3) 1 (0.1) 141 (0.3)	Health region	· · ·	, , , , , , , , , , , , , , , , , , ,	· · ·	<0.001
Arecibo 197 (0.4) 4 (0.2) 193 (0.4) Bayamon 1041 (2.1) 26 (1.6) 1015 (2.1) Caguas 588 (1.2) 28 (1.7) 560 (1.2) Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Linknown 142 (0.3) 1 (0.1) 141 (0.3)	Aguadilla	44 (0.1)	2 (0.1)	42 (0.1)	
Bayamon 1041 (2.1) 26 (1.6) 1015 (2.1) Caguas 588 (1.2) 28 (1.7) 560 (1.2) Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Linknown 142 (0.3) 1 (0.1) 141 (0.3)	Arecibo	197 (0.4)	4 (0.2)	193 (0.4)	
Caguas 588 (1.2) 28 (1.7) 560 (1.2) Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Unknown 142 (0.3) 1 (0.1) 141 (0.3)	Bavamon	1041 (2.1)	26 (1,6)	1015 (2.1)	
Fajardo 359 (0.7) 16 (1.0) 343 (0.7) Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Linknown 142 (0.3) 1 (0.1) 141 (0.3)	Caguas	588 (1.2)	28 (1,7)	560 (1.2)	
Mayaguez 118 (0.2) 6 (0.4) 112 (0.2) Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Linknown 142 (0.3) 1 (0.1) 141 (0.3)	Faiardo	359 (0.7)	16 (1,0)	343 (0.7)	
Metro 6523 (13.1) 352 (21.5) 6171 (12.8) Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) Unknown 142 (0.3) 1 (0.1) 141 (0.3)	Mavaquez	118 (0.2)	6 (0.4)	112 (0.2)	
Ponce 40667 (81.9) 1205 (73.5) 39462 (82.1) 142 (0.3) 1 (0.1) 141 (0.3)	Metro	6523 (13.1)	352 (21.5)	6171 (12.8)	
$\frac{142}{03} + \frac{141}{01} + \frac{141}{03}$	Ponce	40667 (81.9)	1205 (73.5)	39462 (82.1)	
	Unknown	142 (0.3)	1 (0.1)	141 (0.3)	

Previous DENV infection ^a (N = 2062)				0.003
Yes	1703 (82.6)	564 (79.1)	1139 (84.4)	
No	359 (17.4)	149 (20.9)	210 (15.6)	
Traveled to another country in past two weeks	1501 (3.0)	74 (4.5)	1427 (3.0)	0.001
Household member with dengue	619 (1.2)	133 (8.1)	486 (1.0)	<0.001
Reported mosquito bites in past month	8557 (17.2)	624 (38.0)	7933 (16.5)	<0.001
Comorbidities			. ,	
Chronic pulmonary disease or asthma	9721 (19.6)	331 (20.2)	9390 (19.5)	0.544
Cancer	907 (1.8)	26 (1.6)	881 (1.8)	0.519
Chronic kidney disease	607 (1.2)	12 (0 7)	595 (1.2)	0.085
Congenital heart disease	1822 (3.7)	52 (3.2)	1770 (3.7)	0.307
Diabetes	4065 (8.2)	105 (6 4)	3960 (8.2)	0.009
High cholesterol	3034 (6.1)	80 (4.9)	2954 (6.1)	0.039
Hypertension	6664 (13.4)	147 (9.0)	6517 (13.6)	<0.001
Arthritis	1954 (3.9)	22 (1.3)	1932 (4.0)	<0.001
Thyroid disease	2980 (6.0)	69 (4.2)	2911 (6.1)	0.002
Obesity	9221 (18.6)	199 (12.1)	9022 (18.8)	<0.001
Gastritis	531 (1.1)	27 (1.6)	504 (1.0)	0.028
Warning signs⁵				
Persistent vomiting	9401 (18.9)	409 (24.9)	8992 (18.7)	<0.001
Abdominal pain	17476 (35.2)	972 (59.3)	16504 (34.4)	<0.001
Restlessness	18500 (37.2)	767 (46.8)	17733 (36.9)	<0.001
Clinical fluid accumulation	2939 (5.9)	87 (5.3)	2852 (5.9)	0.093
Mucosal bleeding	4276 (8.6)	255 (15.5)	4021 (8.4)	<0.001
Hepatomegaly	119 (0.2)	44 (2.7)	75 (0.2)	<0.001
Other clinical signs/symptoms				
Fever	45090 (90.8)	1631 (99.5)	43459 (90.5)	<0.001
Conjunctivitis	1762 (3.5)	133 (8.1)	1629 (3.4)	<0.001
Chills	26690 (53.7)	1309 (79.8)	25381 (52.8)	<0.001
Nausea	23125 (46.5)	1127 (68.7)	21998 (45.8)	<0.001
No appetite	29972 (60.3)	1282 (78.2)	28690 (59.7)	<0.001
Rash	9268 (18.7)	924 (56.3)	8344 (17.4)	<0.001
Yellow skin	793 (1.6)	68 (4.1)	725 (1.5)	<0.001
ltchy skin	6574 (13.2)	603 (36.8)	5971 (12.4)	<0.001
Headache	29778 (59.9)	1383 (84.3)	28395 (59.1)	<0.001
Eye pain	14106 (28.4)	985 (60.1)	13121 (27.3)	<0.001
Myalgia	23983 (48.3)	1221 (74.5)	22762 (47.4)	<0.001
Arthralgia	19948 (40.2)	1020 (62.2)	18928 (39.4)	<0.001
Tachypnea	9965 (20.1)	744 (45.4)	9221 (19.2)	<0.001
Back pain	17666 (35.6)	874 (53.3)	16792 (35.0)	<0.001
Calf pain	12638 (25.4)	605 (36.9)	12033 (25.0)	<0.001
Arthritis	4155 (8.4)	242 (14.8)	3913 (8.1)	<0.001
Nasal discharge	30350 (61.1)	531 (32.4)	29819 (62.1)	<0.001
Sore throat	22632 (45.6)	599 (36.5)	22033 (45.9)	<0.001
Cough	33842 (68.1)	702 (42.8)	33140 (69.0)	<0.001
Diarrhea	13803 (27.8)	709 (43.2)	13094 (27.3)	<0.001
Hypotension	1327 (2.7)	133 (8.1)	1194 (2.5)	<0.001
Narrow pulse pressure	828 (1.7)	39 (2.4)	789 (1.6)	0.284
Seizure	654 (1.3)	28 (1.7)	626 (1.3)	0.156
Capillary refill <3	2955 (5.9)	99 (6.0)	2856 (5.9)	0.889
Pale skin	11276 (22.7)	772 (47.1)	10504 (21.9)	<0.001

Blue lips	734 (1.5)	70 (4.3)	664 (1.4)	<0.001
Leukopenia	3757 (7.6)	968 (59.0)	2789 (5.8)	<0.001
Thrombocytopenia	4811 (9.7)	738 (45.0)	4073 (8.5)	<0.001
Monthly dengue incidence per 1000 people	0 01 [0 00, 0 02]	0 12 [0 04, 0 32]	0 01 [0 00, 0 02]	<0.001

^a Previous DENV infection was defined as a positive DENV IgG test result collected within 5 days of symptom onset.
 ^b Hemoconcentration (an increase in hematocrit due to plasma loss) is a known warning sign for severe dengue but was excluded from this study, as it requires serial measurements that are challenging to obtain at initial patient contact. To maintain applicability for early, point-of-care diagnosis, we focused on predictors available at first presentation.

307

Among the 1,640 dengue cases, the most frequent symptoms were fever (99.5%, an inclusion criterion for SEDSS), headache (84.3%), and chills (79.8%) (Table 1). Common warning signs included abdominal pain (59.3%), restlessness (46.8%), and persistent vomiting (24.9%). Additionally, 59.0% of cases presented with leukopenia and 45.0% had thrombocytopenia.

312

313 Variable Selection

314 We identified key demographic, clinical, and laboratory characteristics significantly associated 315 with dengue infection (Table S1) and created feature sets with 8 (OR>6 or <0.17), 20 (OR>3 or <0.33), 316 32 (OR>2 or <0.50), and 48 (p<0.05) variables, allowing us to assess the impact of different feature 317 combinations on model accuracy (Table S1). The 8-variable feature set included age group, days post 318 onset, rash, fever, leukopenia, thrombocytopenia, hepatomegaly, and self-reported history of dengue in a 319 household member from participant questionnaire. The 20-variable set was derived from the 8-variable 320 set, adding reported recent mosquito bites, chills, itchy skin, headache, chronic arthritis, eye pain, 321 myalgia, tachypnea, nasal discharge, hypotension, pale skin, and blue lips. The 32-variable set also 322 included diagnosis month, abdominal pain, conjunctivitis, nausea, arthralgia, diarrhea, cough, yellow 323 skin, no appetite, back pain, mucosal bleeding, and dengue monthly incidence in Puerto Rico. The 48-324 variable set also included sex, health region, recent travel, arthritis, sore throat, calf pain, gastritis, narrow 325 pulse pressure, persistent vomiting, restlessness, hypertension, thyroid disease, chronic kidney disease, 326 diabetes, high cholesterol, and obesity. Chronic pulmonary disease, cancer, congenital heart disease,

- 327 clinical fluid accumulation, seizure, and capillary refill <3 seconds were not associated with dengue
- infection at p<0.05 and were not included in ML models.
- 329

330 Performance evaluation

- In addition to the multivariable LR, we used a diverse range of ML algorithms to predict the
- probability of dengue infection. These ML models offer the advantage of adapting to complex data
- patterns and potentially improving diagnostic accuracy.
- The 8-variable feature set had the lowest estimated AUC values across all models, ranging from
- 85.2% to 87.1% on the test set (Fig 1, Fig 2, Table 2). As the feature set size increased, AUCs
- progressively improved. The 20-variable set achieved 89.0% ~ 89.5% AUC, and the 32-variable set
- reached 91.3% ~ 94.2% AUC. The 48-variable set showed minimal further improvement (91.3% ~
- 338 94.7%) compared to the 32-variable set.
- 339
- 340 Fig 1. ROC curves of Logistic Regression, Support Vector Machine, Random Forest, Adaptive
- Boosting, Light Gradient Boosting, and Extreme Gradient Boosting models for (A) 8-, (B) 20-, (C)
- 342 32-, and (D) 48-variable feature sets, SEDSS, May 2012–June 2024. The area under the receiver
- 343 operating characteristic curve is shown.
- 344
- Fig 2. Forest plot of AUC values for Logistic Regression, Support Vector Machine, Random Forest,
- Adaptive Boosting, Light Gradient Boosting, and Extreme Gradient Boosting models for (A) 8-, (B)
- 347 20-, (C) 32-, and (D) 48-variable feature sets, SEDSS, May 2012–June 2024. DeLong method was
- used to obtain the 95% confidence intervals for the AUC-ROC.
- 349

Table 2 Performance of each a	laorithm for predictin	a denaue infection on the	test set SEDSS Ma	av 2012-June 2024
	igonum for predicum	y dengue miection on the		ay 2012-June 2024

Model	Accuracy	Sensitivity	Specificity	PPV	NPV	F1 Score	Kappa	AUC
8-variable feature set								
Logistic Regression	0.8049	0.8821	0.7276	0.7641	0.8606	0.8189	0.6098	0.8672

Support Vector Machine	0.7734	0.8679	0.6789	0.7299	0.8371	0.7929	0.5467	0.8521
Random Forest	0.7998	0.9004	0.6992	0.7496	0.8753	0.8181	0.5996	0.8588
Artificial Neural Network	0.8089	0.8720	0.7459	0.7744	0.8535	0.8203	0.6179	0.8690
Adaptive Boosting	0.8089	0.8821	0.7358	0.7695	0.8619	0.8224	0.6179	0.8700
Light Gradient Boosting	0.8069	0.8963	0.7175	0.7603	0.8738	0.8228	0.6138	0.8701
eXtreme Gradient Boosting	0.8100	0.8516	0.7683	0.7861	0.8381	0.8176	0.6199	0.8706
20-variable feature set								
Logistic Regression	0.8211	0.8476	0.7947	0.8050	0.8391	0.8257	0.6423	0.8905
Support Vector Machine	0.8079	0.8760	0.7398	0.7710	0.8565	0.8202	0.6159	0.8901
Random Forest	0.8120	0.8760	0.7480	0.7766	0.8578	0.8233	0.6240	0.8896
Artificial Neural Network	0.8191	0.8557	0.7825	0.7973	0.8443	0.8255	0.6382	0.8911
Adaptive Boosting	0.8211	0.8577	0.7846	0.7992	0.8465	0.8275	0.6423	0.8919
Light Gradient Boosting	0.8262	0.8374	0.8150	0.8191	0.8337	0.8281	0.6524	0.8943
eXtreme Gr <i>a</i> dient Boosting	0.8201	0.8780	0.7622	0.7869	0.8621	0.8300	0.6402	0.8945
32-variable feature set								
Logistic Regression	0.8394	0.8272	0.8516	0.8479	0.8313	0.8374	0.6789	0.9126
Support Vector Machine	0.8343	0.8862	0.7825	0.8029	0.8730	0.8425	0.6687	0.9130
Random Forest	0.8628	0.8740	0.8516	0.8549	0.8711	0.8643	0.7256	0.9318
Artificial Neural Network	0.8415	0.8659	0.8171	0.8256	0.8590	0.8452	0.6829	0.9117
Adaptive Boosting	0.8648	0.8801	0.8496	0.8540	0.8763	0.8669	0.7297	0.9380
Light Gradient Boosting	0.8740	0.8882	0.8598	0.8636	0.8849	0.8758	0.7480	0.9414
eXtreme Gr <i>a</i> dient Boosting	0.8730	0.8760	0.8699	0.8707	0.8753	0.8734	0.7459	0.9424
48-variable feature set								
Logistic Regression	0.8547	0.8699	0.8394	0.8442	0.8658	0.8569	0.7093	0.9134
Support Vector Machine	0.8547	0.8598	0.8496	0.8511	0.8583	0.8554	0.7093	0.9168
Random Forest	0.8659	0.8740	0.8577	0.8600	0.8719	0.8669	0.7317	0.9385
Artificial Neural Network	0.8547	0.8923	0.8171	0.8299	0.8835	0.8599	0.7093	0.9185
Adaptive Boosting	0.8730	0.8598	0.8862	0.8831	0.8634	0.8713	0.7459	0.9401
Light Gradient Boosting	0.8770	0.9207	0.8333	0.8467	0.9131	0.8822	0.7541	0.9456
eXtreme Gradient Boosting	0.8791	0.8618	0.8963	0.8926	0.8664	0.8769	0.7581	0.9465

PPV: positive predictive value; **NPV**: negative predictive value; **AUC**: area under receiver operating characteristic curve. 350

351 Among ML models, LightGBM and XGBoost consistently achieved the highest AUC across all 352 feature sets, outperforming multivariable LR, SVM, and ANN by ~3% for the 32- and 48-variable sets. 353 This higher performance is likely due to their ability to efficiently handle large feature spaces, capture 354 complex interactions, and prevent overfitting through advanced regularization techniques. Despite this, 355 even simpler models like LR achieved strong performance with AUCs of 91% for the larger feature sets 356 (32 and 48 variables), suggesting that core features captured a substantial amount of the predictive signal. 357 AUC values exceeded 93% for all models in the 32- and 48-variable sets when evaluated on the training 358 set (S4 Table).

359	All models had high sensitivity (>84%) across feature sets (Table 2). Specificity was lower for
360	the 8-variable set (67.9 ~ 76.8%) but improved to >85% for most models in the 32- and 48-variable sets.
361	XGBoost with 48-variables achieved the highest overall AUC (94.7%), with corresponding sensitivity
362	and specificity of 86.2% and 89.6%, respectively. Adding IgG testing improved the performance of
363	XGBoost models across all feature sets, increasing AUC values by 2.6%, 2.0%, 0.5%, and 0.2% for the 8-
364	, 20-, 32-, and 48-variable sets, respectively (S5 Table). Excluding leukopenia and thrombocytopenia
365	from the XGBoost models resulted in a decrease in AUC values, ranging from 0.5% for the 48-variable
366	set to 5.5% for the 8-variable set.
367	F1 scores consistently exceeded 82% across all models for the 20-, 32-, and 48-variable sets,
368	indicating a good balance of precision (correct positive predictions out of all positive predictions) and
369	recall (correct positive predictions out of all actual positives). Kappa values were highest (~0.75) for
370	LightGBM and XGBoost for the 32- and 48-variable feature sets, suggesting good agreement between
371	model predictions and actual classifications, beyond what would be expected by chance.

372

373 Feature importance

374 For the 8- and 20- variable sets, leukopenia was the top-performing feature for SVM, ANN, RF, 375 LightGBM, XGBoost, and LR, followed by thrombocytopenia and rash (S1 Fig, S2 Fig, S6 Table). Age 376 group, days post onset, eye pain, and absence of nasal discharge also emerged as important predictors for 377 RF, LightGBM, and XGBoost. In contrast, AdaBoost identified blue lips, hepatomegaly, and hypotension 378 as the highest scoring features. AdaBoost focuses on creating a series of weak learners (typically decision 379 stumps) and combines them to form a strong classifier. It gives more weight to misclassified instances in 380 subsequent iterations, which can result in a different feature importance profile as the model emphasizes 381 different aspects of the data to improve accuracy. For the 32- and 48- variable sets, monthly dengue 382 incidence showed the highest predictive power for SVM, RF, ANN, LightGBM, XGBoost, and LR (S3 383 Fig, S4 Fig).

384	In the subanalysis where the most important features identified by the highest performing ML
385	model, XGBoost, were sequentially added to the feature set, we observed variable improvements in AUC
386	values (S5 Fig). The initial addition of two variables increased the AUC by 2.8%, suggesting a substantial
387	enhancement in model performance with the inclusion of high-priority predictors. As more variables were
388	added, the gains in AUC became marginal, with incremental improvements ranging from 0% to 1.5%. By
389	quantifying the gains in AUC through sequential addition of important features, this analysis highlights
390	that a relatively small set of highly predictive features can achieve substantial diagnostic performance,
391	reinforcing the utility of ML-based feature selection in optimizing clinical models.

392

393 **Discussion**

394 The use of various ML algorithms, including RF, AdaBoost, LightGBM, and XGBoost, 395 demonstrate significant improvements in diagnostic accuracy for dengue infection compared to traditional 396 methods. Prior research has shown that the diagnostic accuracy of the 1997 and 2009 WHO clinical case 397 definitions for dengue has high sensitivity (93%) but low specificity (29% and 31%, respectively), 398 making it challenging to distinguish dengue from other febrile illnesses in clinical settings [45]. With 399 AUC values exceeding 90% for larger feature sets, these models could potentially reduce misdiagnosis 400 rates and improve patient outcomes, especially in settings where rapid tests are either not authorized or 401 limited in availability. Furthermore, ML models can be instrumental during large dengue outbreaks, 402 where rapid triage is essential. For instance, an ANN model developed for dengue severity prognosis demonstrated good performance using demographic information and laboratory test results, indicating 403 404 that ML can quickly predict disease severity and assist in efficient patient triage [20]. Supporting this, 405 other studies have shown high accuracy and effectiveness of ML in dengue diagnosis: an Extra Trees 406 Classifier model achieved over 99% accuracy in Yemen [48], XGBoost reached an AUC of 86% in 407 patients with AFI in Vietnam [49], and Decision Tree and Multilayer Perceptron models attained 98% 408 accuracy in Brazil [50]. Other research on predicting severe COVID-19 in hospitalized children

demonstrated higher diagnostic performance with ML approaches compared to LR, with just a few simpleand easily collected parameters [22].

The identification of key features such as leukopenia, rash, thrombocytopenia, and age group 411 412 aligns with clinical knowledge of dengue presentations, validating the models' ability to capture relevant 413 clinical indicators and suggesting they can effectively complement and enhance existing diagnostic 414 processes. Leukopenia and thrombocytopenia are well-documented hematological manifestations of 415 dengue, indicating the disease's impact on the blood cell count [51] and were identified as key predictive 416 variables in a similar study [20]. Although these hematological markers substantially contributed to 417 model performance, particularly in smaller feature sets, the XGBoost model with the 48-variable set 418 excluding leukopenia and thrombocytopenia achieved an AUC of 94.1%, demonstrating that strong 419 predictive performance can be attained without relying solely on these laboratory values. This finding 420 highlights the potential for accurate dengue prediction in resource-limited settings where access to CBCs 421 may be restricted. Although IgG testing modestly improved AUCs, its limited availability, potential for 422 misinterpretation in routine clinical practice, and reliance on specialized laboratory infrastructure 423 compared to readily available CBCs restrict its utility as a routine diagnostic tool. The inclusion of age 424 group is consistent with other ML prediction models [20, 22] and highlights the varying clinical 425 presentations and risks across different age demographics, underscoring the need for age-specific 426 diagnostic approaches. Rash, while common in dengue, is also seen in various other febrile illnesses and 427 should be considered alongside other symptoms for differential diagnosis [53]. Similarly, the absence of 428 nasal discharge, more indicative of respiratory pathogens, can also aid in differentiation. Other similar 429 studies also identified body temperature [20] and duration of fever [21] as important features. 430 Identifying monthly dengue incidence as a key feature underscores the value of temporal patterns 431 for accurate dengue prediction. However, the impact of this data may vary depending on its granularity. 432 While our study highlights potential benefits, other research suggests that using broader regional 433 incidence data may yield smaller improvements compared to more localized data reflecting the specific

transmission dynamics in a patient's area [21]. These findings suggest the need for real-time surveillance

and timely intervention strategies, potentially leading to more effective public health responses during
peak transmission periods [54]. By leveraging localized monthly incidence data, healthcare systems can
better allocate resources, anticipate outbreaks, and implement targeted prevention measures, ultimately
reducing the burden of dengue on communities.

439 Despite the high performance of advanced models like XGBoost, it is noteworthy that simpler 440 models like multivariable LR also achieved AUCs of 91% for the larger feature sets. This indicates that a 441 substantial portion of the predictive power lies within core features, potentially making LR a more 442 interpretable and computationally efficient option for some applications. However, for the larger feature 443 sets, gradient boosting models (XGBoost, LightGBM, AdaBoost) outperformed LR, SVM, and ANN, 444 which may be attributed to the gradient boosting models' ability to better capture complex feature 445 interactions and non-linear relationships within the data. Gradient boosting models are inherently 446 designed to improve prediction accuracy by iteratively focusing on the hardest-to-predict cases, which can 447 be particularly advantageous when dealing with larger and more complex feature sets. On the other hand, 448 consistently lower AUC values for SVM and ANN across all feature sets in our study suggest potential 449 challenges these models face in capturing intricate feature interactions and effectively generalizing from 450 the data. Specifically, ANNs may struggle with high-dimensional datasets due to the "curse of 451 dimensionality," where the addition of more features can lead to sparse data, making patterns harder to 452 identify [55]. This, coupled with the risk of overfitting—where the model memorizes the training data but 453 fails to generalize well to unseen data—can reduce accuracy, increase training times, and decrease 454 interpretability. These factors contribute to the observed performance gap between ANNs and the gradient 455 boosting models, particularly as the feature set size grows.

The observation that the performance improvement between the 32-variable and 48-variable sets is minimal suggests a point of diminishing returns. Here, additional features contribute little to predictive power while potentially increasing model complexity and training time. Thus, while ensemble methods like XGBoost may be preferable for applications where maximizing predictive accuracy is paramount, it is important to weigh the benefits of added complexity against the potential gains in performance.

While some models demonstrated high sensitivity, others prioritized specificity, highlighting the need to carefully consider the desired balance between correctly identifying true positives (high sensitivity) and minimizing false positives (high specificity) for specific clinical applications. Another study from Thailand suggests that incorporating dengue NS1 rapid test results enhances diagnostic specificity in models like Bayesian networks, indicating potential for similar improvements in our ML models, which could better confirm non-dengue cases when combined with clinical and laboratory data [21].

468 This study was subject to several limitations. First, the dataset's heavy skew towards data from 469 the 2012-2013 outbreak and its primary focus on DENV-1 may limit the generalizability of the models to 470 other periods, regions, or serotypes. Future research should focus on validating these models in diverse 471 settings, integrating real-time data, and exploring the inclusion of newer diagnostic features to refine their 472 accuracy and applicability further. Second, although more features generally improve model performance, 473 there is a risk of overfitting, especially with smaller datasets. Third, the models were developed using data 474 from SEDSS, where the inclusion criteria required febrile illness. This criterion may limit the 475 generalizability of the models to populations without similar inclusion criteria. Fourth, as diagnostic tools, 476 these models would need to be re-fitted to different variables and populations to ensure their accuracy and 477 applicability across various settings. Fifth, the SEDSS dataset used in this study is systematically 478 collected and robust, which may not accurately reflect the conditions of real-world datasets. In many real-479 world applications, data from electronic health records can be sparse, contain free text fields, or have 480 incomplete information. This could affect the model's performance if it were trained on less-structured 481 data.

This study demonstrates the potential of ML models, particularly XGBoost and LightGBM, to improve dengue diagnostic accuracy. By incorporating a wider range of features, including temporal patterns like monthly dengue incidence, these models achieved high AUC values, exceeding 90% for larger feature sets. This enables early and precise diagnosis, which could lead to improved patient outcomes and reduced viral spread during outbreaks, particularly in resource-scarce settings where the

487	availability of rapid tests is often constrained. Furthermore, our findings highlight the importance of both
488	complex ensemble methods and simpler models. While XGBoost and LightGBM offer superior
489	performance, even LR achieved strong accuracy with core features. However, careful consideration of
490	model interpretability, generalizability, and continuous validation are crucial for real-world
491	implementation. It is important to note that these ML models are intended to aid and improve dengue
492	diagnosis rather than replace current methods, such as laboratory testing. Future research should focus on
493	addressing these aspects to ensure robust and generalizable ML models that can empower clinicians and
494	public health authorities to effectively manage and control dengue worldwide.
495	To facilitate clinical application, developing a user-friendly tool such as a calculator, Shiny app,
496	or web-based interface to implement the prediction model is a crucial next step. This would bridge the
497	gap between complex ML models and clinical practice, allowing for efficient integration into routine care
498	and potentially improving diagnostic accuracy and timeliness.

499

500 Acknowledgments

501 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily

represent the official position of the US Centers for Disease Control and Prevention.

503 **References**

- Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. Dengue. Lancet.
 2024;403(10427):667-82.
- Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems.
 Archives of medical research. 2002;33(4):330-42.
- 3. Madewell ZJ. Arboviruses and Their Vectors. South Med J. 2020;113(10):520-3.
- 509 4. Simmons CP, Farrar JJ, Nguyen v V, Wills B. Dengue. N Engl J Med. 2012;366(15):1423-32.
- 5. Toan NT, Rossi S, Prisco G, Nante N, Viviani S. Dengue epidemiology in selected endemic
 countries: factors influencing expansion factors as estimates of underreporting. Trop Med Int
 Health. 2015;20(7):840-63.
- 513 6. Undurraga EA, Halasa YA, Shepard DS. Use of expansion factors to estimate the burden of
 514 dengue in Southeast Asia: a systematic analysis. PLoS Negl Trop Dis. 2013;7(2):e2056.
- 515 7. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7.
- S17 8. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.
 S19 Lancet. 2018;392(10159):1736-88.
- 520 9. Sharp TM, Ryff KR, Santiago GA, Margolis HS, Waterman SH. Lessons Learned from Dengue
 521 Surveillance and Research, Puerto Rico, 1899-2013. Emerg Infect Dis. 2019;25(8):1522-30.
- 522 10. Centers for Disease Control and Prevention. ArboNET 2024 [cited 2024 August 19]. Available
 523 from: <u>https://www.cdc.gov/mosquitoes/php/arbonet/index.html</u>.
- Ryff KR, Rivera A, Rodriguez DM, Santiago GA, Medina FA, Ellis EM, et al. Epidemiologic
 Trends of Dengue in U.S. Territories, 2010-2020. MMWR Surveill Summ. 2023;72(4):1-12.
- Méndez-Lázaro P, Muller-Karger F, Otis D, Mccarthy M, Peña-Orellana M. Assessing Climate
 Variability Effects on Dengue Incidence in San Juan, Puerto Rico. International Journal of
 Environmental Research and Public Health. 2014;11(9):9409-28.
- Wong JM, Volkman HR, Adams LE, García CO, Martinez-Quiñones A, Perez-Padilla J, et al.
 Clinical Features of COVID-19, Dengue, and Influenza among Adults Presenting to Emergency
 Departments and Urgent Care Clinics—Puerto Rico, 2012–2021. The American Journal of
 Tropical Medicine and Hygiene. 2023;108(1):107.
- Wong J, Horwitz MM, Zhou L, Toh S. Using machine learning to identify health outcomes from
 electronic health record data. Curr Epidemiol Rep. 2018;5(4):331-42.
- 15. Rocha FP, Giesbrecht M. Machine learning algorithms for dengue risk assessment: a case study
 for São Luís do Maranhão. Computational and Applied Mathematics. 2022;41(8):393.
- 16. Nasir M, Summerfield NS, Carreiro S, Berlowitz D, Oztekin A. A machine learning approach for
 diagnostic and prognostic predictions, key risk factors and interactions. Health Services and
 Outcomes Research Methodology. 2024.
- Lai CK, Leung E, He Y, Cheung CC, Oliver MOY, Yu Q, et al. A machine learning-based risk
 score for prediction of infective endocarditis among patients with Staphylococcus aureus
 bacteraemia The SABIER score. J Infect Dis. 2024.
- Tiwari P, Colborn KL, Smith DE, Xing F, Ghosh D, Rosenberg MA. Assessment of a Machine
 Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of
 Incident Atrial Fibrillation. JAMA Netw Open. 2020;3(1):e1919396.
- Ho TS, Weng TC, Wang JD, Han HC, Cheng HC, Yang CC, et al. Comparing machine learning
 with case-control models to identify confirmed dengue cases. PLoS Negl Trop Dis.
 2020;14(11):e0008843.

549 20. Huang SW, Tsai HP, Hung SJ, Ko WC, Wang JR. Assessing the risk of dengue severity using 550 demographic information and laboratory test results with machine learning. PLoS Negl Trop Dis. 2020;14(12):e0008960. 551 552 21. Sa-Ngamuang C, Haddawy P, Luvira V, Piyaphanee W, Iamsirithaworn S, Lawpoolsri S. 553 Accuracy of dengue clinical diagnosis with and without NS1 antigen rapid test: Comparison 554 between human and Bayesian network model decision. PLoS Negl Trop Dis. 555 2018;12(6):e0006573. 556 22. Liu P, Xing Z, Peng X, Zhang M, Shu C, Wang C, et al. Machine learning versus multivariate 557 logistic regression for predicting severe COVID-19 in hospitalized children with Omicron variant 558 infection. J Med Virol. 2024;96(2):e29447. 559 23. Tomashek KM, Rivera A, Torres-Velasquez B, Hunsperger EA, Munoz-Jordan JL, Sharp TM, et 560 al. Enhanced Surveillance for Fatal Dengue-Like Acute Febrile Illness in Puerto Rico, 2010-561 2012. PLoS Negl Trop Dis. 2016;10(10):e0005025. 562 Madewell ZJ, Hernandez-Romieu AC, Wong JM, Zambrano LD, Volkman HR, Perez-Padilla J, 24. 563 et al. Sentinel Enhanced Dengue Surveillance System - Puerto Rico, 2012-2022. MMWR Surveill 564 Summ. 2024;73(3):1-29. 565 25. Read JS, Torres-Velasquez B, Lorenzi O, Rivera Sanchez A, Torres-Torres S, Rivera LV, et al. 566 Symptomatic Zika Virus Infection in Infants, Children, and Adolescents Living in Puerto Rico. 567 JAMA Pediatr. 2018:172(7):686-93. 568 26. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap 569 consortium: Building an international community of software platform partners. J Biomed 570 Inform. 2019;95:103208. 571 27. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data 572 capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81. 573 574 28. Siriseriwan W. smotefamily: A Collection of Oversampling Techniques for Class Imbalance 575 Problem Based on SMOTE 2024 [cited 2024 June 17]. Available from: https://cran.r-576 project.org/web/packages/smotefamily/index.html. Kuhn M. caret: Classification and Regression Training 2023 [cited 2024 June 17]. Available 577 29. from: https://cran.r-project.org/web/packages/caret/index.html. 578 579 30. Breiman L. Random forests. Machine learning. 2001;45:5-32. 580 31. Hearst MA, Dumais ST, Osuna E, Platt J, Scholkopf B. Support vector machines. IEEE 581 Intelligent Systems and their applications. 1998;13(4):18-28. 582 Yegnanarayana B. Artificial neural networks: PHI Learning Pvt. Ltd.; 2009. 32. 583 Schapire RE. The boosting approach to machine learning: An overview. Nonlinear estimation and 33. 584 classification. 2003:149-71. 585 Bentéjac C, Csörgő A, Martínez-Muñoz G. A comparative analysis of gradient boosting 34. 586 algorithms. Artificial Intelligence Review. 2021:54:1937-67. Breiman L. randomForest: Breiman and Cutler's Random Forests for Classification and 587 35. 588 Regression 2022 [cited 2024 June 17]. Available from: https://cran.r-589 project.org/web/packages/randomForest/index.html. 590 Meyer D. e1071: Misc Functions of the Department of Statistics, Probability Theory Group 36. 591 (Formerly: E1071), TU Wien 2023 [cited 2024 June 20]. Available from: https://cran.r-592 project.org/web/packages/e1071/index.html. Ripley B. nnet: Feed-Forward Neural Networks and Multinomial Log-Linear Models 2023 [cited 593 37. 594 2024 June 18]. Available from: https://cran.r-project.org/web/packages/nnet/index.html. 595 38. Culp M. ada: The R Package Ada for Stochastic Boosting 2016 [cited 2024 June 18]. Available 596 from: https://cran.r-project.org/web/packages/ada/index.html. 597 39. Shi Y. lightgbm: Light Gradient Boosting Machine 2024 [cited 2024 June 17]. Available from: 598 https://cran.r-project.org/web/packages/lightgbm/index.html.

599	40.	Chen T. xgboost: Extreme Gradient Boosting 2024 [cited 2024 June 17]. Available from:
600		https://cran.r-project.org/web/packages/xgboost/index.html.
601	41.	DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more
602		correlated receiver operating characteristic curves: a nonparametric approach. Biometrics.
603		1988;44(3):837-45.
604	42.	Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-5.
605	43.	Altmann A, Toloși L, Sander O, Lengauer T. Permutation importance: a corrected feature
606		importance measure. Bioinformatics. 2010;26(10):1340-7.
607	44.	R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
608		Foundation for Statistical Computing; 2024
609	45.	Raafat N, Loganathan S, Mukaka M, Blacksell SD, Maude RJ. Diagnostic accuracy of the WHO
610		clinical definitions for dengue and implications for surveillance: A systematic review and meta-
611		analysis. PLoS Negl Trop Dis. 2021:15(4):e0009359.
612	46.	Sigera PC, Amarasekara R, Rodrigo C, Rajapakse S, Weeratunga P, De Silva NL, et al. Risk
613		prediction for severe disease and better diagnostic accuracy in early dengue infection: the
614		Colombo dengue study. BMC Infect Dis. 2019;19(1):680.
615	47.	Meiía MFÁ, Shu P-Y, Ji D-D. Accuracy of Dengue, Chikungunya, and Zika diagnoses by
616		primary healthcare physicians in Tegucigalpa, Honduras, BMC Infectious Diseases.
617		2023:23(1):371.
618	48.	Abdualgalil B. Abraham S. M. Ismael W. Early Diagnosis for Dengue Disease Prediction Using
619		Efficient Machine Learning Techniques Based on Clinical Data, 2022, 2022;3(3):12.
620	49.	Ming DK, Tuan NM, Hernandez B, Sangkaew S, Vuong NL, Chanh HO, et al. The Diagnosis of
621	.,,,	Dengue in Patients Presenting With Acute Febrile Illness Using Supervised Machine Learning
622		and Impact of Seasonality. Front Digit Health. 2022:4:849641.
623	50.	Bohm BC, Borges FEM, Silva SCM, Soares AT, Ferreira DD, Belo VS, et al. Utilization of
624	001	machine learning for dengue case screening. BMC Public Health. 2024;24(1):1573.
625	51.	Vogt MB, Lahon A, Arva RP, Spencer Clinton JL, Rico-Hesse R, Dengue viruses infect human
626		megakaryocytes, with probable clinical consequences, PLoS Negl Trop Dis
627		2019:13(11):e0007837.
628	52	Teo A Tan HD Lov T Chia PY Chua CLL Understanding antibody-dependent enhancement in
629	021	dengue: Are afucosylated IgG1s a concern? PLoS Pathog. 2023;19(3):e1011223.
630	53.	Daumas RP. Passos SRL, Oliveira RVC, Nogueira RMR, Georg I, Marzochi KBF, Brasil P.
631	001	Clinical and laboratory features that discriminate dengue from other febrile illnesses: a diagnostic
632		accuracy study in Rio de Janeiro Brazil BMC Infectious Diseases 2013:13(1):77
633	54.	Madewell ZJ, Hemme RR, Adams L, Barrera R, Waterman SH, Johansson MA, Comparing
634	0.11	vector and human surveillance strategies to detect arbovirus transmission. A simulation study for
635		Zika virus detection in Puerto Rico. PLoS Negl Tron Dis. 2019;13(12):e0007988
636	55.	Grohs P. Ibragimov S. Jentzen A. Koppensteiner S. Lower bounds for artificial neural network
637		approximations: A proof that shallow neural networks fail to overcome the curse of
638		dimensionality. Journal of Complexity, 2023:77:101746.
639		



